- Home
- INBS vs APRE Comparison
INBS vs APRE Comparison
Compare INBS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBS
- APRE
- Stock Information
- Founded
- INBS 2016
- APRE 2006
- Country
- INBS United States
- APRE United States
- Employees
- INBS N/A
- APRE N/A
- Industry
- INBS Medical Specialities
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INBS Health Care
- APRE Health Care
- Exchange
- INBS Nasdaq
- APRE Nasdaq
- Market Cap
- INBS 16.4M
- APRE 13.5M
- IPO Year
- INBS N/A
- APRE 2019
- Fundamental
- Price
- INBS $1.50
- APRE $1.87
- Analyst Decision
- INBS
- APRE Strong Buy
- Analyst Count
- INBS 0
- APRE 2
- Target Price
- INBS N/A
- APRE $15.50
- AVG Volume (30 Days)
- INBS 144.8K
- APRE 21.0K
- Earning Date
- INBS 05-07-2025
- APRE 05-13-2025
- Dividend Yield
- INBS N/A
- APRE N/A
- EPS Growth
- INBS N/A
- APRE N/A
- EPS
- INBS N/A
- APRE N/A
- Revenue
- INBS $3,031,405.00
- APRE $1,502,581.00
- Revenue This Year
- INBS $280.88
- APRE N/A
- Revenue Next Year
- INBS $126.26
- APRE N/A
- P/E Ratio
- INBS N/A
- APRE N/A
- Revenue Growth
- INBS 23.21
- APRE 157.63
- 52 Week Low
- INBS $1.00
- APRE $1.85
- 52 Week High
- INBS $4.09
- APRE $6.70
- Technical
- Relative Strength Index (RSI)
- INBS 32.78
- APRE 26.70
- Support Level
- INBS $1.34
- APRE $2.17
- Resistance Level
- INBS $2.21
- APRE $2.30
- Average True Range (ATR)
- INBS 0.19
- APRE 0.17
- MACD
- INBS -0.08
- APRE -0.01
- Stochastic Oscillator
- INBS 14.68
- APRE 2.50
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.